Novel therapeutic agents that modulate neurokinin receptors
CA 2319159 A1 · Owner: Marquess, Daniel · Inventors: Marquess, Daniel; Higgins, Deborah L.; Griffin, John H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel multi-binding compounds (agents) which bind neurokinin receptors are used to treat disorders in mammals that are mediated by the neurokinin receptors, such as Parkinson's disease Alzheimer's disease, depression, anxiety inflammation, rheumatoid arthritis, cystitis osteoarthritis, irritable bowel syndrome allergic rhinitis, pain, chronic pain, migraine headaches, asthma, bronchitis and chemotherapy induced emesis. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological processes/functions thereof. Each of the ligands is covalently attached to a linker or linkers which may be the same or different …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 7, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 7, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 7, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.